Cesarean Infection Prevention: Major Effects on 4 Outcomes
An evidence synthesis on cesarean infection prevention covering pre-incision cefazolin, adjunctive azithromycin (C/SOAP), vaginal preparation, chlorhexidine skin antisepsis, and concurrent prophylactic tranexamic acid (TRAAP2) — across four key perioperative outcomes.
One-Minute Takeaway on Cesarean Infection Prevention
One-Minute Takeaway
- Cesarean infection prevention is built on pre-incision cefazolin within 60 minutes of skin incision, with weight-based dosing for higher BMI.
- Adjunctive azithromycin 500 mg IV (C/SOAP trial) reduces composite endometritis and wound infection by approximately half in cesareans performed during labor or after rupture of membranes.
- Vaginal preparation immediately before cesarean with povidone-iodine or chlorhexidine reduces endometritis risk per Cochrane meta-analysis (RR ~0.41).
- Chlorhexidine-alcohol skin antisepsis is favored over iodine-alcohol per the Tuuli 2016 NEJM randomized trial.
- Prophylactic tranexamic acid after cord clamping (TRAAP2) modestly reduces postpartum hemorrhage; TXA addresses bleeding rather than infection but is part of the contemporary perioperative bundle.
Why Cesarean Infection Prevention Matters
Cesarean delivery is the most common major surgery performed in the United States, with approximately 1.2 million performed annually and a national rate near 32% of births. Postoperative infectious morbidity — endometritis, surgical site infection, urinary tract infection, and bacteremia — is the principal source of preventable maternal harm in this surgical population. Cesarean infection prevention is therefore a high-volume, high-impact quality improvement target.
Without prophylaxis, endometritis after cesarean occurs in approximately 20 to 25% of cases, with surgical site infection in 3 to 15% depending on patient and surgical factors. Pre-incision cefazolin reduces this morbidity substantially and is now standard. The Mackeen 2014 Cochrane review pooled randomized trials of antibiotic timing and reported a relative risk for endometritis of approximately 0.43 with pre-incision versus after-cord-clamp dosing.
Cesarean infection prevention has expanded beyond single-agent cefazolin into a multi-component bundle. The C/SOAP trial (Tita 2016) demonstrated that adjunctive azithromycin added to cefazolin further reduces composite infectious morbidity by approximately half in non-elective cesareans. Vaginal preparation (Haas 2020 Cochrane) and chlorhexidine-alcohol skin antisepsis (Tuuli 2016 NEJM) are additional bundle elements supported by randomized data.
Concurrent perioperative interventions also include prophylactic tranexamic acid (TXA) for postpartum hemorrhage prevention. The TRAAP2 trial (Sentilhes 2021) demonstrated a modest reduction in postpartum hemorrhage with prophylactic TXA after cord clamping. While TXA addresses hemorrhage rather than infection, it is part of the contemporary perioperative bundle reviewed alongside cesarean infection prevention measures.
The evidence base on each bundle element is strong individually. The integrated bundle — pre-incision cefazolin, azithromycin add-on for non-elective cesarean, vaginal preparation, chlorhexidine skin antisepsis, and TXA where indicated — represents the contemporary standard for perioperative care at cesarean delivery in current ACOG and SMFM guidance.
What Evidence Was Reviewed
This synthesis draws on the C/SOAP randomized trial of adjunctive azithromycin (Tita 2016, NEJM), the Mackeen 2014 Cochrane review of antibiotic timing, the Smaill & Grivell 2014 Cochrane review of any antibiotic prophylaxis, the Tuuli 2016 NEJM RCT of skin antiseptics, the Haas 2020 Cochrane review of vaginal preparation, the Caissutti 2017 systematic review and meta-analysis of vaginal cleansing, the TRAAP2 randomized trial of prophylactic TXA (Sentilhes 2021, NEJM), the WOMAN trial of TXA in established postpartum hemorrhage, the Pevzner 2011 pharmacokinetic study informing weight-based cefazolin dosing, and the ACOG Practice Bulletin No. 199 on perioperative antibiotic prophylaxis.
Together these sources include more than 25,000 women across cesarean infection prevention trials and pharmacokinetic studies, with primary outcomes spanning endometritis, surgical site infection, urinary tract infection, postpartum hemorrhage, and tissue antibiotic concentrations. The integrated evidence supports the contemporary multi-element bundle approach.
| Study / Source | Design | n | Comparison | Primary Outcome |
|---|---|---|---|---|
| C/SOAP (Tita 2016, NEJM) | RCT | 2,013 | Cefazolin + azithromycin vs cefazolin alone (non-elective) | Composite endometritis/wound infection within 6 wk |
| Mackeen 2014 (Cochrane timing) | SR/MA | 5,041 (10 RCTs) | Pre-incision vs after-cord-clamp | Endometritis, wound infection |
| Smaill & Grivell 2014 (Cochrane) | SR/MA | ~14,000 | Any antibiotic vs none/placebo | Postoperative infection |
| Tuuli 2016 (NEJM) | RCT | 1,147 | Chlorhexidine-alcohol vs iodine-alcohol | SSI within 30 d |
| Haas 2020 (Cochrane vaginal prep) | SR/MA | ~7,000 (21 RCTs) | Vaginal antiseptic prep vs none | Endometritis, postoperative fever |
| Caissutti 2017 (Obstet Gynecol) | SR/MA | ~5,000 (16 RCTs) | Vaginal prep with povidone-iodine | Endometritis |
| Yildirim 2012 (Arch Gynecol Obstet) | RCT | 338 | Povidone-iodine vaginal prep vs none | Endometritis |
| TRAAP2 (Sentilhes 2021, NEJM) | RCT | 4,551 | 1 g IV TXA after cord clamp vs placebo | PPH > 1,000 mL |
| WOMAN (Lancet 2017) | RCT | 20,060 | TXA vs placebo for established PPH | Death from bleeding, hysterectomy |
| Pevzner 2011 (Obstet Gynecol) | Pharmacokinetic study | 40 | Cefazolin tissue levels by BMI | Adipose / myometrium concentrations |
| Sutton 2015 (Am J Obstet Gynecol) | Pharmacokinetic study | 30 | Azithromycin maternal/cord PK | Plasma and tissue levels |
| ACOG PB No. 199 (2018) | Practice bulletin | Synthesis | Antimicrobial prophylaxis framework | Recommendations |
Key Findings — Synthesised by Theme
Theme 1 — Pre-Incision Cefazolin Is the Foundation
Pre-incision cefazolin within 60 minutes of skin incision is the foundation of cesarean infection prevention. The Mackeen 2014 Cochrane review of 10 randomized trials reported a relative risk for endometritis of approximately 0.43 (95% CI 0.28–0.65) with pre-incision versus after-cord-clamp dosing, with similar reductions for wound infection and other postoperative infections.
Cefazolin 2 g intravenous is standard; the dose is increased to 3 g for women weighing 120 kg or more, supported by the Pevzner 2011 pharmacokinetic study showing inadequate adipose tissue concentrations at 2 g in higher-BMI patients. The Smaill & Grivell 2014 Cochrane review confirmed that any antibiotic prophylaxis substantially reduces postoperative infection compared with no prophylaxis, with pooled RR of approximately 0.40 for endometritis and 0.36 for wound infection.
Theme 2 — Adjunctive Azithromycin Reduces Composite Infection in Non-Elective Cesarean
The C/SOAP trial (Tita 2016, NEJM) randomized 2,013 women undergoing cesarean delivery during labor or after rupture of membranes to receive 500 mg intravenous azithromycin or placebo, in addition to standard cefazolin. The primary composite outcome of endometritis, wound infection, or other infection within 6 weeks occurred in 6.1% (azithromycin) versus 12.0% (placebo), a relative risk of 0.51 (95% CI 0.38–0.68).
The number needed to treat to prevent one infection was approximately 17. The benefit was driven primarily by reductions in endometritis and wound infection. ACOG and SMFM endorsements followed, supporting adjunctive azithromycin for cesareans performed in labor or after rupture of membranes; the C/SOAP population did not include elective cesareans with intact membranes, where benefit is plausible but not directly trial-tested.
Theme 3 — Vaginal Preparation Reduces Endometritis
Vaginal preparation with povidone-iodine or chlorhexidine solution immediately before cesarean reduces endometritis risk. The Haas 2020 Cochrane review pooled 21 randomized trials and reported a relative risk for endometritis of approximately 0.41 (95% CI 0.29–0.59). The Caissutti 2017 systematic review reached similar conclusions.
The benefit was most pronounced in cesareans performed in labor or after rupture of membranes, where the bacterial burden in the lower genital tract is highest. Standard implementation involves a 30-second to 1-minute vaginal sponge or swab with antiseptic solution before draping. Both povidone-iodine and chlorhexidine appear effective in pooled estimates; head-to-head comparisons remain limited.
Theme 4 — Chlorhexidine-Alcohol Skin Prep Reduces SSI
The Tuuli 2016 NEJM randomized trial compared chlorhexidine-alcohol with iodine-alcohol skin preparation in 1,147 women undergoing cesarean. The composite surgical site infection rate (superficial or deep wound infection within 30 days) was 4.0% (chlorhexidine) versus 7.3% (iodine), a relative risk of 0.55 (95% CI 0.34–0.90).
The result aligns with the broader surgical literature favoring chlorhexidine-alcohol antisepsis and informs current cesarean infection prevention bundle recommendations. ACOG and CDC surgical site infection prevention guidance favor chlorhexidine-based skin antisepsis as standard for cesarean delivery.
Theme 5 — Prophylactic TXA Reduces Postpartum Hemorrhage (TRAAP2)
Prophylactic tranexamic acid (TXA) after cord clamping reduces postpartum hemorrhage at cesarean delivery. The TRAAP2 trial (Sentilhes 2021, NEJM) randomized 4,551 women undergoing elective or non-elective cesarean to receive 1 g intravenous TXA after umbilical cord clamping or placebo. Postpartum hemorrhage greater than 1,000 mL occurred in 26.7% (TXA) versus 31.6% (placebo), a relative risk of 0.84 (95% CI 0.75–0.94).
Secondary outcomes including need for additional uterotonics and transfusion showed mixed effects with smaller magnitude. Thromboembolic events were not significantly increased in the TRAAP2 active arm. TXA addresses postpartum hemorrhage rather than infection but is part of the contemporary perioperative bundle alongside cesarean infection prevention measures and is reviewed here for clinical completeness.
Clinical pearl — The dominant clinical question in modern cesarean infection prevention is no longer “does prophylaxis work” — it is “how completely is the bundle implemented.” Each element (pre-incision cefazolin, azithromycin add-on for non-elective, vaginal prep, chlorhexidine skin prep) is supported by Tier 1 evidence, and integrated bundle adherence is the principal practice target.
The C/SOAP protocol used 500 mg intravenous azithromycin infused over 1 hour, started up to 1 hour before skin incision (concurrent with or immediately after cefazolin). Sutton 2015 pharmacokinetic data supported that this timing achieves adequate maternal serum and adipose concentrations at incision. The trial population was non-elective cesarean (in labor or after rupture of membranes); ACOG guidance applies the recommendation to that population specifically.
The C/SOAP trial randomized women undergoing cesarean during labor or after rupture of membranes; elective cesareans with intact membranes were excluded. ACOG Practice Bulletin No. 199 reflects this trial population, recommending adjunctive azithromycin in the same non-elective scenario. Some authors have argued for extrapolation to all cesareans given the favorable safety profile, but RCT evidence in elective populations remains limited and current US guidance does not extend the recommendation.
Both povidone-iodine and chlorhexidine vaginal preparations have been studied with consistent endometritis reduction signals. The Haas 2020 Cochrane review pooled both solutions and did not find a significant difference between them in indirect comparison. Choice in practice is often driven by institutional formulary, allergy/sensitivity considerations, and clinician preference. Povidone-iodine is most commonly studied; chlorhexidine is acceptable where institutional preference favors it.
Preoperative chlorhexidine bathing is recommended in general surgical SSI prevention guidance and is increasingly included in cesarean bundles. The randomized evidence base specifically in cesarean is smaller than for skin preparation at incision; adoption rests on extrapolation from broader surgical literature. CDC and SHEA guidance support its inclusion as a low-cost, low-harm intervention. It is reasonable to include but should not displace higher-yield bundle elements (pre-incision cefazolin, vaginal prep, chlorhexidine skin antisepsis).
Oxytocin remains the cornerstone uterotonic for postpartum hemorrhage prevention and is independent of TXA. TXA is an antifibrinolytic — it inhibits plasmin-mediated fibrinolysis rather than augmenting uterine contraction. The TRAAP2 trial layered TXA on top of routine oxytocin and showed an additional modest reduction in postpartum hemorrhage. The WOMAN trial (Lancet 2017) demonstrated mortality benefit of TXA in established postpartum hemorrhage when given within 3 hours, supporting its dual role in prevention and treatment.
Quality & Consistency of the Evidence
Evidence quality across the cesarean infection prevention literature is high for each individual bundle element. The C/SOAP trial, the Mackeen 2014 and Smaill & Grivell 2014 Cochrane reviews, the Tuuli 2016 NEJM RCT, the Haas 2020 Cochrane review, and the TRAAP2 NEJM trial provide concordant Tier 1 evidence for the major findings.
What the Evidence Does Not Show
Several specific gaps remain in the cesarean infection prevention evidence base. Naming these gaps explicitly is more useful than the generic “more research is needed” framing.
Specific evidence gaps
- Adjunctive azithromycin in elective cesarean with intact membranes has not been directly evaluated in a large RCT; the C/SOAP trial population was limited to non-elective cesareans, and current ACOG guidance reflects this.
- Direct head-to-head trials of povidone-iodine versus chlorhexidine vaginal preparation are limited; both appear effective in pooled estimates but the optimal solution remains unsettled.
- Optimal cefazolin dosing in extreme obesity (BMI > 40) is not fully resolved by available pharmacokinetic data; some authors advocate further dose escalation beyond 3 g, while RCT outcome data are smaller.
- Bundle versus individual element randomization is uncommon — most evidence is element-by-element, leaving the marginal benefit of each addition to a fully implemented bundle imprecisely characterized.
- Prophylactic TXA dosing optimization (1 g vs alternative regimens, weight-based dosing in obesity) is not fully resolved by TRAAP2; the trial used a fixed 1 g dose regardless of weight.
- Preoperative chlorhexidine bathing has supportive general-surgical evidence but limited cesarean-specific RCT data; adoption rests on extrapolation.
In addition, the comparative effectiveness of cesarean infection prevention measures in low-resource settings — where antibiotic availability, surgical instrument sterilization, and infection rates differ substantially from high-resource trials — is not well characterized by the predominantly North American and European trial base.
Practical Implications for Cesarean Infection Prevention
Based on the current evidence, the following considerations may inform cesarean infection prevention practice. These are framed as evidence-based considerations rather than directive recommendations; clinical judgement, patient-specific allergies, institutional protocol, and local antibiograms should guide individual decisions.
Implementation should be tailored to institutional protocol, formulary, and patient-specific factors (allergy, weight, intact vs ruptured membranes, elective vs non-elective). The principal practice target in cesarean infection prevention is no longer demonstrating efficacy of individual elements but ensuring complete and timely bundle implementation across every cesarean delivery.
Evidence Grade & Bottom Line
Overall Evidence Grade — Strong (for pre-incision cefazolin, C/SOAP azithromycin in non-elective cesarean, Haas vaginal prep, Tuuli skin prep, and TRAAP2 prophylactic TXA); Moderate (for weight-based cefazolin dosing); Limited (for azithromycin in elective cesarean, head-to-head povidone-iodine vs chlorhexidine vaginal prep, and bundle vs individual-element marginal effects). The evidence supporting current cesarean infection prevention bundle elements is unlikely to shift fundamentally with further research, although optimization questions remain active.
Bottom Line
- Pre-incision cefazolin within 60 minutes of skin incision is the foundation of cesarean infection prevention, with weight-based dosing for higher BMI.
- Adjunctive azithromycin 500 mg IV reduces composite infectious morbidity by approximately half in cesareans performed during labor or after rupture of membranes (C/SOAP).
- Vaginal preparation with povidone-iodine or chlorhexidine immediately before cesarean reduces endometritis risk per pooled Cochrane evidence.
- Chlorhexidine-alcohol skin antisepsis is supported over iodine-alcohol for surgical site infection prevention at cesarean (Tuuli 2016).
- Prophylactic tranexamic acid after cord clamping modestly reduces postpartum hemorrhage (TRAAP2); TXA addresses bleeding rather than infection but is part of the contemporary perioperative bundle.
Article Information & References
For Educational Purposes Only
This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages, antibiotic selections, and bundle protocols should be verified against current prescribing information, institutional protocols, and the most recent ACOG and SMFM statements.
References
- Tita ATN, Szychowski JM, Boggess K, et al. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2016;375(13):1231–1241. DOI: 10.1056/NEJMoa1602044
- Mackeen AD, Packard RE, Ota E, Berghella V, Baxter JK. Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. Cochrane Database Syst Rev. 2014;(12):CD009516. DOI: 10.1002/14651858.CD009516.pub2
- Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev. 2014;(10):CD007482. DOI: 10.1002/14651858.CD007482.pub3
- Tuuli MG, Liu J, Stout MJ, et al. A Randomized Trial Comparing Skin Antiseptic Agents at Cesarean Delivery. N Engl J Med. 2016;374(7):647–655. DOI: 10.1056/NEJMoa1511048
- Haas DM, Morgan S, Contreras K, Kimball S. Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. Cochrane Database Syst Rev. 2020;(4):CD007892. DOI: 10.1002/14651858.CD007892.pub7
- Caissutti C, Saccone G, Zullo F, et al. Vaginal Cleansing Before Cesarean Delivery: A Systematic Review and Meta-analysis. Obstet Gynecol. 2017;130(3):527–538. DOI: 10.1097/AOG.0000000000002167
- Yildirim G, Güngördük K, Asicioğlu O, et al. Does vaginal preparation with povidone-iodine prior to caesarean delivery reduce the risk of endometritis? Arch Gynecol Obstet. 2012;286(5):1145–1149. DOI: 10.1007/s00404-012-2440-1
- Sentilhes L, Sénat MV, Le Lous M, et al; Groupe de Recherche en Obstétrique et Gynécologie. Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. N Engl J Med. 2021;384(17):1623–1634. DOI: 10.1056/NEJMoa2028788
- WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–2116. DOI: 10.1016/S0140-6736(17)30638-4
- Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE Jr. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011;117(4):877–882. DOI: 10.1097/AOG.0b013e31820b95e4
- Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Andrews WW. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. Am J Obstet Gynecol. 2015;212(6):812.e1–6. DOI: 10.1016/j.ajog.2015.01.015
- Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283. DOI: 10.2146/ajhp120568
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstet Gynecol. 2018;132(3):e103–e119. DOI: 10.1097/AOG.0000000000002833